TapewireFind a company

person · Reporting owner

Amoroso Michael

Disclosed activity across 2 companies

Tapewire entity
41656
SEC CIK
0001830874

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ABEONA THERAPEUTICS INC.ABEO · Entity 5808DirectorJanuary 26, 2026January 27, 2026
PRECISION BIOSCIENCES INCDTIL · Entity 6284Director · President and CEOJune 01, 2026June 03, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ABEONA THERAPEUTICS INC.

Report date January 26, 2026 · Filed January 27, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect217,779 Reported balance After 2026-01-26 transaction · row 1
1 source row

Row 1 · 2026-01-26 · Grant · Acquired 37,313 · Balance 217,779

F1: All of the restricted stock will vest on January 26, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: All of the restricted stock will vest on January 26, 2027.

PRECISION BIOSCIENCES INC

Report date June 01, 2026 · Filed June 03, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect573,888 Reported balance After 2026-06-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-06-01 · Grant · Acquired 573,888 · Balance 573,888

F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

F2: Award vests in three substantially equal annual installments beginning on February 18, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

F2: Award vests in three substantially equal annual installments beginning on February 18, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 01, 2026 Filed Jun 3, 2026 20:05 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 GrantRestricted Stock Units · Derivative 573,888 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-040212 · wk-form4_1780517107.xml · derivative · entry 1

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 573,888

Underlying: Common Stock · 573,888 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: Award vests in three substantially equal annual installments beginning on February 18, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F2 · derivative.expiration_date: Award vests in three substantially equal annual installments beginning on February 18, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
February 18, 2026 Filed Feb 19, 2026 21:31 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 SaleCommon Stock 20,559 $3.84 $78,946.56
Disclosure

SEC source: 0001628280-26-009804 · wk-form4_1771536666.xml · nonDerivative · entry 2

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 243,392

F3 · kind: The sales were effected pursuant to a Rule 10b5-1 plan adopted on August 2, 2024. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:31 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 67,797 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-009804 · wk-form4_1771536666.xml · derivative · entry 3

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 135,593

Underlying: Common Stock · 67,797 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: RSUs vests in three substantially equal annual installments beginning on February 17, 2026, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F4 · derivative.expiration_date: RSUs vests in three substantially equal annual installments beginning on February 17, 2026, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:31 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 67,797 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-009804 · wk-form4_1771536666.xml · nonDerivative · entry 1

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 263,951

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the vesting of Restricted Stock Units ("RSUs") on February 17, 2026.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
January 26, 2026 Filed Jan 27, 2026 21:30 UTC ABEONA THERAPEUTICS INC. ABEO · Entity 5808 GrantCommon Stock 37,313 $0.00 $0.00
Disclosure

SEC source: 0001493152-26-003806 · ownership.xml · nonDerivative · entry 1

Amoroso Michael · CIK 0001830874 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 217,779

F1 · shares: All of the restricted stock will vest on January 26, 2027.

Read SEC document
January 22, 2026 Filed Jan 22, 2026 23:49 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 SaleCommon Stock 34,799 $4.17 $145,111.83
Disclosure

SEC source: 0001628280-26-003149 · wk-form4_1769125738.xml · nonDerivative · entry 4

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 196,154

F3 · kind: The sales were effected pursuant to a Rule 10b5-1 plan adopted on August 2, 2024. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.97 to $4.30. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote

Read SEC document
January 20, 2026 Filed Jan 22, 2026 23:49 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 69,421 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-003149 · wk-form4_1769125738.xml · derivative · entry 7

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 69,421

Underlying: Common Stock · 69,421 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F7 · derivative.exercise_date: On August 22, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F7 · derivative.expiration_date: On August 22, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
January 20, 2026 Filed Jan 22, 2026 23:49 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 37,069 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-003149 · wk-form4_1769125738.xml · derivative · entry 6

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,069

Underlying: Common Stock · 37,069 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F6 · derivative.exercise_date: On April 18, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F6 · derivative.expiration_date: On April 18, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
January 20, 2026 Filed Jan 22, 2026 23:49 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 8,888 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-003149 · wk-form4_1769125738.xml · derivative · entry 5

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,888 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F5 · derivative.exercise_date: On January 20, 2023 the Reporting Person was granted RSUs, which vested in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F5 · derivative.expiration_date: On January 20, 2023 the Reporting Person was granted RSUs, which vested in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
January 20, 2026 Filed Jan 22, 2026 23:49 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 69,421 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-26-003149 · wk-form4_1769125738.xml · nonDerivative · entry 3

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 230,953

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the vesting of Restricted Stock Units ("RSUs") on January 20, 2026.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
January 20, 2026 Filed Jan 22, 2026 23:49 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 37,069 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-26-003149 · wk-form4_1769125738.xml · nonDerivative · entry 2

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 161,532

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the vesting of Restricted Stock Units ("RSUs") on January 20, 2026.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
January 20, 2026 Filed Jan 22, 2026 23:49 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 8,888 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-26-003149 · wk-form4_1769125738.xml · nonDerivative · entry 1

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 124,463

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the vesting of Restricted Stock Units ("RSUs") on January 20, 2026.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
November 03, 2025 Filed Nov 4, 2025 21:15 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 9,444 $0.00 $0.00
Disclosure

SEC source: 0001628280-25-048855 · wk-form4_1762290924.xml · derivative · entry 3

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,444 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: On November 2, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on November 2, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. The RSUs vested in full on November 2, 2025.

F4 · derivative.expiration_date: On November 2, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on November 2, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. The RSUs vested in full on November 2, 2025.

Read SEC document
November 03, 2025 Filed Nov 4, 2025 21:15 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 SaleCommon Stock 3,409 $6.49 $22,124.41
Disclosure

SEC source: 0001628280-25-048855 · wk-form4_1762290924.xml · nonDerivative · entry 2

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 115,575

F3 · kind: The sales were effected pursuant to a Rule 10b5-1 plan adopted on August 2, 2024. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.

Read SEC document
November 02, 2025 Filed Nov 4, 2025 21:15 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 9,444 $0.00 $0.00
Disclosure

SEC source: 0001628280-25-048855 · wk-form4_1762290924.xml · nonDerivative · entry 1

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 118,984

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the vesting and settlement of Restricted Stock Units ("RSUs") on November 2, 2025.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
June 02, 2025 Filed Jun 4, 2025 21:00 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 GrantRestricted Stock Units · Derivative 203,390 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-081721 · ownership.xml · derivative · entry 1

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 203,390

Underlying: Common Stock · 203,390 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: Award vests in three substantially equal annual installments beginning on February 17, 2026, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F2 · derivative.expiration_date: Award vests in three substantially equal annual installments beginning on February 17, 2026, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
March 24, 2025 Filed Mar 25, 2025 22:00 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 SaleCommon Stock 964 $5.56 $5,359.84
Disclosure

SEC source: 0000950170-25-044599 · ownership.xml · nonDerivative · entry 2

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 109,540

F3 · kind: The sales were effected pursuant to a Rule 10b5-1 plan adopted on August 2, 2024. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.

Read SEC document
March 21, 2025 Filed Mar 25, 2025 22:00 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 3,417 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-044599 · ownership.xml · derivative · entry 3

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,417 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: On March 21, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 21, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. The RSUs vested in full on March 21, 2025.

F4 · derivative.expiration_date: On March 21, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 21, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. The RSUs vested in full on March 21, 2025.

Read SEC document
March 21, 2025 Filed Mar 25, 2025 22:00 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 3,417 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-044599 · ownership.xml · nonDerivative · entry 1

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 110,504

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the vesting of Restricted Stock Units ("RSUs") on March 21, 2025.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
January 31, 2025 Filed Feb 4, 2025 01:37 UTC ABEONA THERAPEUTICS INC. ABEO · Entity 5808 GrantCommon Stock 36,101 $0.00 $0.00
Disclosure

SEC source: 0001493152-25-004750 · ownership.xml · nonDerivative · entry 1

Amoroso Michael · CIK 0001830874 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 180,466

F1 · kind: Upon vesting, a portion of the restricted stock may be surrendered to satisfy the reporting person's tax withholding obligation. Any deemed disposition of the withheld shares would be exempt pursuant to Rule 16b-3(e).

F2 · shares: All of the restricted stock will vest on January 31, 2026.

Read SEC document
January 21, 2025 Filed Jan 23, 2025 02:00 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 SaleCommon Stock 36,838 $4.67 $172,033.46
Disclosure

SEC source: 0000950170-25-008013 · ownership.xml · nonDerivative · entry 2

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 107,087

F3 · kind: The sales were effected pursuant to a Rule 10b5-1 plan adopted on August 2, 2024. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.

Read SEC document
January 20, 2025 Filed Jan 23, 2025 02:00 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 69,421 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-008013 · ownership.xml · derivative · entry 5

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 138,842

Underlying: Common Stock · 69,421 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F6 · derivative.exercise_date: On August 22, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F6 · derivative.expiration_date: On August 22, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
January 20, 2025 Filed Jan 23, 2025 02:00 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 37,079 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-008013 · ownership.xml · derivative · entry 4

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 74,138

Underlying: Common Stock · 37,079 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F5 · derivative.exercise_date: On April 18, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F5 · derivative.expiration_date: On April 18, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
January 20, 2025 Filed Jan 23, 2025 02:00 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 8,888 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-008013 · ownership.xml · derivative · entry 3

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,888

Underlying: Common Stock · 8,888 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: On January 20, 2023 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F4 · derivative.expiration_date: On January 20, 2023 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
January 20, 2025 Filed Jan 23, 2025 02:00 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 115,388 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-008013 · ownership.xml · nonDerivative · entry 1

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 143,925

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on January 20, 2025.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
November 04, 2024 Filed Nov 6, 2024 00:14 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 SaleCommon Stock 3,012 $8.19 $24,668.28
Disclosure

SEC source: 0000950170-24-121726 · ownership.xml · nonDerivative · entry 2

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,537

F3 · kind: The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.

Read SEC document
November 02, 2024 Filed Nov 6, 2024 00:14 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 9,443 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-121726 · ownership.xml · derivative · entry 3

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,444

Underlying: Common Stock · 9,443 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: On November 2, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on November 2, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F4 · derivative.expiration_date: On November 2, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on November 2, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
November 02, 2024 Filed Nov 6, 2024 00:14 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 9,443 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-121726 · ownership.xml · nonDerivative · entry 1

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,549

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the vesting of Restricted Stock Units ("RSUs") on November 2, 2024.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
August 26, 2024 Filed Aug 27, 2024 23:07 UTC ABEONA THERAPEUTICS INC. ABEO · Entity 5808 GrantCommon Stock 11,797 $0.00 $0.00
Disclosure

SEC source: 0001493152-24-034052 · ownership.xml · nonDerivative · entry 1

Amoroso Michael · CIK 0001830874 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 144,365

F1 · kind: The acquisition was exempt pursuant to Rule 16b-3(d).

F2 · shares: This stock grant represents the remainder of the 2024 annual grant to board of directors. This portion of the annual stock grant was withheld until all employees/management were allocated their shares and in order to enable onboarding of two new Board members. All of the restricted stock will vest on August 26, 2025.

Read SEC document
August 22, 2024 Filed Aug 23, 2024 11:30 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 GrantRestricted Stock Units · Derivative 208,263 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-100019 · ownership.xml · derivative · entry 1

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 208,263

Underlying: Common Stock · 208,263 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: Award vests in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F2 · derivative.expiration_date: Award vests in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
July 08, 2024 Filed Jul 9, 2024 20:35 UTC ABEONA THERAPEUTICS INC. ABEO · Entity 5808 GrantCommon Stock 23,611 $0.00 $0.00
Disclosure

SEC source: 0001493152-24-026645 · ownership.xml · nonDerivative · entry 1

Amoroso Michael · CIK 0001830874 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 132,568

F1 · shares: All of the restricted stock will vest on July 8, 2025.

Read SEC document
May 08, 2024 Filed May 9, 2024 00:26 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 GrantCommon Stock 8,334 $12.00 $100,008.00
Disclosure

SEC source: 0000950170-24-056141 · ownership.xml · nonDerivative · entry 1

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,106

F1 · shares: Represents shares purchased through a definitive subscription agreement, pursuant to which the Issuer agreed to issue and sell shares of its common stock in a non-brokered private placement to certain members of its management.

Read SEC document
May 02, 2024 Filed May 3, 2024 22:29 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 SaleCommon Stock 1,526 $10.32 $15,748.32
Disclosure

SEC source: 0000950170-24-053112 · ownership.xml · nonDerivative · entry 2

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,772

F4 · kind: The sales were effected pursuant to a Rule 10b5-1 plan adopted on March 24, 2022. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.11 to $10.53. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.

Read SEC document
May 01, 2024 Filed May 3, 2024 22:29 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 3,417 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-053112 · ownership.xml · derivative · entry 3

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,417

Underlying: Common Stock · 3,417 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

F6 · derivative.exercise_date: On March 21, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 21, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F6 · derivative.expiration_date: On March 21, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 21, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
May 01, 2024 Filed May 3, 2024 22:29 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 3,417 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-053112 · ownership.xml · nonDerivative · entry 1

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,298

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the partial vesting of Restricted Stock Units ("RSUs") on March 21, 2024, and subsequent settlement of such vested RSUs on May 1, 2024.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

F3 · balance_after: On February 13, 2024, the Issuer effected a 1-for-30 reverse stock split. The amounts of securities herein have been adjusted to reflect the reverse stock split.

Read SEC document
April 18, 2024 Filed Apr 23, 2024 01:12 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 GrantRestricted Stock Units · Derivative 111,217 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-046598 · ownership.xml · derivative · entry 1

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 111,217

Underlying: Common Stock · 111,217 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: Award vests in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F2 · derivative.expiration_date: Award vests in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
January 22, 2024 Filed Jan 24, 2024 00:17 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 SaleCommon Stock 137,390 $0.36 $49,460.40
Disclosure

SEC source: 0001209191-24-002119 · doc4.xml · nonDerivative · entry 2

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 356,433

F3 · kind: The sales were effected pursuant to a Rule 10b5-1 plan adopted on March 24, 2022. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.

Read SEC document
January 20, 2024 Filed Jan 24, 2024 00:17 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 266,720 $0.00 $0.00
Disclosure

SEC source: 0001209191-24-002119 · doc4.xml · derivative · entry 3

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 533,280

Underlying: Common Stock · 266,720 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share.

F4 · derivative.exercise_date: On January 20, 2023 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F4 · derivative.expiration_date: On January 20, 2023 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
January 20, 2024 Filed Jan 24, 2024 00:17 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 266,720 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-24-002119 · doc4.xml · nonDerivative · entry 1

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 493,823

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on January 20, 2024.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share.

Read SEC document
November 03, 2023 Filed Nov 6, 2023 22:07 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 SaleCommon Stock 125,025 $0.40 $50,010.00
Disclosure

SEC source: 0001209191-23-054549 · doc4.xml · nonDerivative · entry 2

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 227,103

F3 · kind: The sales were effected pursuant to a Rule 10b5-1 plan adopted on March 24, 2022. The transaction was a sell-to-cover, with shares sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs.

Read SEC document
November 02, 2023 Filed Nov 6, 2023 22:07 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 283,390 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-054549 · doc4.xml · derivative · entry 3

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 566,610

Underlying: Common Stock · 283,390 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share.

F4 · derivative.exercise_date: On November 2, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on November 2, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F4 · derivative.expiration_date: On November 2, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on November 2, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
November 02, 2023 Filed Nov 6, 2023 22:07 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 283,390 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-054549 · doc4.xml · nonDerivative · entry 1

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 352,128

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on November 2, 2023.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share.

Read SEC document
September 27, 2023 Filed Sep 29, 2023 20:30 UTC ABEONA THERAPEUTICS INC. ABEO · Entity 5808 SaleCommon Stock 5,508 $3.91 $21,542.34
Disclosure

SEC source: 0001493152-23-034855 · ownership.xml · nonDerivative · entry 1

Amoroso Michael · CIK 0001830874 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,957

F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with vesting of restricted stock awards.

F2 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $3.8200 to $4.2000 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
September 20, 2023 Filed Sep 22, 2023 20:05 UTC ABEONA THERAPEUTICS INC. ABEO · Entity 5808 SaleCommon Stock 327 $3.90 $1,275.30
Disclosure

SEC source: 0001493152-23-033446 · ownership.xml · nonDerivative · entry 1

Amoroso Michael · CIK 0001830874 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 114,465

F1 · kind: The transaction reported in this Form 4 was to cover tax obligations associated with vesting of restricted stock awards.

Read SEC document
June 20, 2023 Filed Jun 21, 2023 20:05 UTC ABEONA THERAPEUTICS INC. ABEO · Entity 5808 SaleCommon Stock 338 $4.45 $1,504.10
Disclosure

SEC source: 0001493152-23-021996 · ownership.xml · nonDerivative · entry 1

Amoroso Michael · CIK 0001830874 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 114,792

F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with vesting of restricted stock awards.

Read SEC document
June 14, 2023 Filed Jun 16, 2023 20:05 UTC ABEONA THERAPEUTICS INC. ABEO · Entity 5808 GrantCommon Stock 58,689 $4.62 $271,143.18
Disclosure

SEC source: 0001493152-23-021653 · ownership.xml · nonDerivative · entry 1

Amoroso Michael · CIK 0001830874 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 115,130

F1 · shares: All of the restricted stock will vest on June 14, 2024.

Read SEC document
March 22, 2023 Filed Mar 23, 2023 20:00 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 SaleCommon Stock 46,999 $0.82 $38,539.18
Disclosure

SEC source: 0001209191-23-020716 · doc4.xml · nonDerivative · entry 2

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 68,738

F3 · kind: The sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover, with shares sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs.

Read SEC document
March 21, 2023 Filed Mar 23, 2023 20:00 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 102,535 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-020716 · doc4.xml · derivative · entry 3

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 205,009

Underlying: Common Stock · 102,535 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: On March 21, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 21, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F4 · derivative.expiration_date: On March 21, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 21, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
March 21, 2023 Filed Mar 23, 2023 20:00 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 102,535 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-020716 · doc4.xml · nonDerivative · entry 1

Amoroso Michael · CIK 0001830874 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 115,737

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on March 21, 2023.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
March 20, 2023 Filed Mar 21, 2023 21:13 UTC ABEONA THERAPEUTICS INC. ABEO · Entity 5808 SaleCommon Stock 268 $2.33 $624.44
Disclosure

SEC source: 0001493152-23-008429 · ownership.xml · nonDerivative · entry 1

Amoroso Michael · CIK 0001830874 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,441

F1 · acquired: The sale reported in this Form 4 was to cover tax obligations associated with vesting of restricted stock awards.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.